Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Minerva Endocrinologica 2019 March;44(1) > Minerva Endocrinologica 2019 March;44(1):58-69

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  UNILATERAL NON-ALDOSTERONE-PRODUCING ADRENOCORTICAL TUMORS 

Minerva Endocrinologica 2019 March;44(1):58-69

DOI: 10.23736/S0391-1977.18.02900-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Clinical and molecular prognostic factors in adrenocortical carcinoma

Rossella LIBÉ

French Network for Adrenal Cancer, Department of Endocrinology, Cochin Hospital, Paris, France



INTRODUCTION: Adrenocortical carcinoma (ACC) is a rare cancer, with an incidence less than 0.7-1.5 per 1 million people per year, with a poor prognosis. The overall survival (OS) depends on the ENSAT stage: in particular in metastatic ACC the OS varies from 10 to 20 months, with a 5-year survival around 10%. ACC has a different behavior, probably due to a different biology. For this reason, a careful prognostic classification is mandatory, in order to stratify the patients and propose a specific management.
EVIDENCE ACQUISITION: Prognostic factors can be divides in three groups: clinical factors (tumor stage, age, hormone-related symptoms), pathological factors (Weiss Score, mitotic count, Ki-67, SF-1 and AVA2, P53, beta-catenin immunohistochemistry, resection status), molecular factors (chromosomal aberrations, methylation profile, altered gene expression and miRNA expression, gene mutations).
EVIDENCE SYNTHESIS: The best way to stratify ACC patients and propose the best therapeutic option is to combine clinical, pathological and molecular factors.
CONCLUSIONS: Individualizing patients’ prognosis and tumor biology appears as a necessary step for personalized medicine. In addition to tumor stage and tumor grade, the genomic classification may precise the risk stratification and thus help defining therapeutic strategy.


KEY WORDS: Adrenocortical carcinoma - Mortality - Survival rate - Prognosis

inizio pagina